Matt Hay serves as the U.S. Director of Advocacy for Metabolics at Alexion Pharmaceuticals, Inc., where he plays a pivotal role in championing the voices of patients affected by rare diseases such as Neurofibromatosis (NF) and Hypophosphatasia (HPP). With a profound commitment to patient advocacy,...
Matt Hay serves as the U.S. Director of Advocacy for Metabolics at Alexion Pharmaceuticals, Inc., where he plays a pivotal role in championing the voices of patients affected by rare diseases such as Neurofibromatosis (NF) and Hypophosphatasia (HPP). With a profound commitment to patient advocacy, Matt ensures that the unique needs and perspectives of these communities are integrated into the decision-making processes that shape treatment options and healthcare policies. His work involves collaborating with cross-functional teams to develop strategic initiatives that amplify patient voices, fostering a culture of inclusivity and responsiveness within the organization.
In his current role, Matt is spearheading key projects that aim to enhance awareness and understanding of NF and HPP, leveraging his extensive background in fundraising, marketing, and business development to drive impactful outreach efforts. His expertise in strategic planning and sales enablement equips him to effectively engage with stakeholders, from healthcare professionals to policymakers, ensuring that the challenges faced by patients are not only recognized but addressed.
Beyond his professional endeavors, Matt is a best-selling author and TEDx speaker, sharing his journey as an Auditory Brainstem Implant user and inspiring others to overcome obstacles. His experiences as an Ironman Triathlon and Boston Marathon finisher exemplify his resilience and determination, qualities that resonate deeply within the rare disease community. Through his multifaceted approach, Matt Hay continues to be a powerful advocate, dedicated to transforming the landscape of care for individuals living with NF and HPP, and empowering them to find and use their voices across the medicine lifecycle.
